Where does Reapplix APS rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Reapplix APS ranks #33,017 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Reapplix APS hold?

Reapplix APS holds 8 US utility patents granted between 2015 and 2024, spanning 10 technology areas.

What is Reapplix APS's Innovation Score?

Reapplix APS has an Innovation Score of 35.0 out of 100 (top 50% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Reapplix APS's patent grant rate increasing or decreasing?

Reapplix APS's recent grant velocity is +67% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Reapplix APS's patents?

Reapplix APS's patents average 16.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Reapplix APS patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Reapplix APS

Q: What technology areas does Reapplix APS focus on?

Reapplix APS's top technology area is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor) with 6 patents, ranking #1,115 of 3,490 assignees active in that subclass. Grants appear in 10 CPC subclasses total.

USPTO PatentsView assignee record - 8 granted patents across 10 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Reapplix ranks #33,017 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 10 technology areas.

#33,017
of 49,997 US assignees by volume: Top 50%
by Innovation Score (35.0/100): 16.0
avg claims per patent: +67%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R33017 · Foreign Corporation #33,017 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #33,017/49,997
PHOTO-FINISH Rayotek Scientific
CPC-FOCUS A61M · 10 areas
INNOV-THIN 35.0/100
CLAIMS-RICH 16.0 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +67% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Rayotek Scientific, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Reapplix’s 35.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (22%) Velocity 6.7 pts (19%) Breadth 11.2 pts (32%) Claim depth 9.6 pts (27%)

Qualcomm Incorporated · highest

85
Reapplix APS · this assignee

35
3D Lighting… · lowest

7

What this shows Reapplix's Innovation Score is 35.0/100 (top 50% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Reapplix?

Each dot is one of Reapplix’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Reapplix’s own 16.0 claims/patent is ABOVE the 14.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Reapplix vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Reapplix's grants concentrate

Reapplix APS is a focused PatentsView assignee: 10 CPC subclasses with 75% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). Peak complete grant year is 2024 (2 grants) versus a trough of 1 in 2015. By volume, Reapplix sits between Rayotek Scientific, Inc. and RED Pacs, LLC.

Reapplix's three-year grant acceleration

Reapplix APS shows 3 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Rayotek Scientific

8
RB&W Manufacturing

8
Re-dai Precision…

8
RE2

8
Rearden Mova

8
Reaxing S R L

8
RED DOG Mobile Sh…

8
RED Pacs

8
Reapplix APS ◀

8

What this shows Reapplix holds 8 patents at rank #32,989, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Reapplix

By rank, the assignees closest to #32,989 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in Reapplix's primary technology class.

Reapplix's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

35 Top 50% higher than 50% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Reapplix APS patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	12.5%
2018	1	12.5%
2019	1	12.5%
2020	1	12.5%
2021	1	12.5%
2022	1	12.5%
2024	2	25.0%

Which technologies does Reapplix APS patent most?

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 6

B04B - Centrifuges 4

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 4

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 4

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 3

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 3

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 3

B01L - Chemical OR Physical Laboratory Apparatus FOR General USE 3

B01D - Separation 2

A61B - DIAGNOSIS; SURGERY; Identification 1

Top 10 of 10 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Reapplix APS's patent record in context - here's where to go next.

Reapplix APS's lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 75% of its portfolio - see every assignee active in that class. Explore A61M
Ranked #33,017 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Reapplix APS against Rayotek Scientific, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 35.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.